Forte Biosciences, Inc.
FBRX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -1.21 | 0.11 | -0.06 | 0.07 |
| FCF Yield | -5.27% | -6.63% | -11.78% | -6.91% |
| EV / EBITDA | -9.44 | -3.95 | -2.64 | -16.75 |
| Quality | ||||
| ROIC | -21.86% | -11.74% | -41.96% | -14.01% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 50.00% |
| Cash Conversion Ratio | 0.79 | 0.89 | 0.66 | 1.40 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | -39.70% | 3.41% | -3.75% | -23.45% |
| Safety | ||||
| Net Debt / EBITDA | 5.08 | 9.18 | 2.85 | 3.03 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -31,806.00 | -34,774.62 | -23,111.05 |